Genmab — Maj 2020
-
No they are apparantly prerecorded. There cant be much discussion...
-
Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis
-
Tak mobbyduck
-
hhmm - nul markedsreaktion
-
-
Amyloidosis market US https://www.grandviewresearch.com/industry-analysis/amyloidosis-treatment-market
-
Tidligere har vi diskuteret 10 - 20% af MM markedet (størrelse). Men nok betydeligt mindre konkurrence i Amylodosis end i MM
-
der er ingen
-
Winkel siger: for which no approved treatments are available
-
673 vistnok
-
7,76
-
6,76
-
Tast usddkk i google
-
Men det er da vist ath på us noteringen?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind